Biopharma firm Agios Q1 product revenue more than doubles, beats estimates

Agios Pharmaceuticals

29/04/2026 11:38

Overview

U.S. biopharmaceutical firm's Q1 product revenue more than doubled, beating analyst expectations

Net loss for Q1 widened yr/yr, reflecting higher R&D and SG&A expenses

Company plans Q2 2026 sNDA submission for mitapivat in sickle cell disease

Outlook

Company plans to submit mitapivat sNDA for sickle cell disease in Q2 2026

Agios expects Phase 2b tebapivat LR-MDS topline results in first half 2026

Company expects Phase 2 tebapivat sickle cell disease topline results in second half 2026

Result Drivers

U.S. LAUNCH OF AQVESME - Q1 U.S. net revenue was driven by the commercial launch of AQVESME (mitapivat) in thalassemia in late January 2026

EX-U.S. SALES - Ex-U.S. net revenue reflected demand for PYRUKYND (mitapivat) in thalassemia in Saudi Arabia

HIGHER OPERATING EXPENSES - R&D and SG&A expenses rose due to pipeline advancement, workforce costs, and activities supporting AQVESME launch

Company press release: ID:nGNX4ySNK1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
Beat
$20.75 mln
$13.65 mln (10 Analysts)
Q1 Net Income
-$99.11 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $41.00, about 65.3% above its April 28 closing price of $24.80

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)